NCT07081763View on ClinicalTrials.gov

Immunotherapy With Baricitinib and Sirolimus, Alone and in Combination, for the Control of HIV-1 Replication After Antiretroviral Treatment Interruption

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

191

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

May 31, 2029

Study Completion Date

November 30, 2030

Conditions
HIV-1-infection
Interventions
DRUG

Baricitinib 2 MG

Administered orally at 2 mg QD from W0 to W10.

DRUG

Sirolimus 2 MG

Administered orally at 2 mg QD from W0 to W10.

OTHER

Placebo of baricitinib 2 MG

Administered orally at 2 mg QD from W0 to W10.

OTHER

Placebo of sirolimus 2 MG

Administered orally at 2 mg QD from W0 to W10.

All Listed Sponsors
lead

ANRS, Emerging Infectious Diseases

OTHER_GOV